HALOZYME THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Posard Matthew L. sold 18,996 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $107.74 ($106.13–$108.99, $2.05M total) across 4 trades on 2026-09-16 under a Rule 10b5-1 trading plan.
Halozyme Therapeutics (HALO) plans to offer $1.05B in convertible senior notes due 2033, with an option for $150M more. Proceeds will fund capped call transactions, repurchase existing notes, and general corporate purposes. The notes are convertible under certain conditions and will accrue interest semi-annually.
Halozyme (HALO) reported record Q2 2026 revenue of $481M, up 48% YOY, and raised full-year guidance. Shares have risen 59% YTD, supported by strong institutional buying and robust fundamentals, including 3-year sales and EPS growth of 28.5% and 28%, respectively.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning HALO (HALOZYME THERAPEUTICS, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent HALO coverage spans earnings, insider activity and financial news.
In the last 30 days, HALO insiders filed 17 SEC Form 4 transactions — no purchases and 17 sales ($12.7M). The most active reporter was Torley Helen, PRESIDENT AND CEO, with 13 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring the stock short-term.
The raise could provide liquidity for repurchasing existing notes and fund acquisitions, but may dilute equity if converted.
Strong top-line growth and upgraded guidance could drive further upside.
Large insider sell may signal confidence concerns, potentially pressuring the stock short term.
Strong earnings beat and revenue growth support a bullish outlook.
AlphAI scores every news story that mentions HALO with an AI model for sentiment and relevance, and aggregates insider trades from HALOZYME THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Posard Matthew L. sold 18,996 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $107.74 ($106.13–$108.99, $2.05M total) across 4 trades on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min readHalozyme Therapeutics (HALO) plans to offer $1.05B in convertible senior notes due 2033, with an option for $150M more. Proceeds will fund capped call transactions, repurchase existing notes, and general corporate purposes. The notes are convertible under certain conditions and will accrue interest semi-annually.
2 min readHalozyme (HALO) reported record Q2 2026 revenue of $481M, up 48% YOY, and raised full-year guidance. Shares have risen 59% YTD, supported by strong institutional buying and robust fundamentals, including 3-year sales and EPS growth of 28.5% and 28%, respectively.
2 min readTorley Helen (PRESIDENT AND CEO) sold 60,000 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $107.28 ($107.01–$108.67, $6.44M total) across 7 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.
1 min readMyriad Genetics (MYGN) reported Q2 revenues of $190.7M, down 10.5% YoY, missing estimates. Its stock fell 40.7% to $3.19. Halozyme Therapeutics (HALO) reported $481M in revenues, up 47.7% YoY, beating estimates. Its stock rose 24.5% to $106.74. Amgen (AMGN) reported $10.05B in revenues, up 9.5% YoY, exceeding expectations. Its stock is flat at $391.29. The market has seen shifts in leadership due to AI and geopolitical concerns.
3 min readHalozyme Therapeutics (HALO) stock rose 36.4% in the past month due to strong Q2 2026 results and raised full-year guidance. The company's ENHANZE drug-delivery technology, licensed to partners like J&J and Roche, drove revenue growth. Royalty revenues increased 46.7% YoY to $373.8M, and total revenues are now projected at $1.84-$1.91B for 2026.
2 min readBioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
3 min readHalozyme (HALO) appointed Dannielle Appelhans to its board, citing her biotech and pharma leadership experience. CEO Helen Torley sold 60,000 shares for $6.28M. HALO's stock closed at $107.62, up 2.60%.
1 min readTorley Helen (PRESIDENT AND CEO) sold 60,000 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $104.59 ($98.96–$107.76, $6.28M total) across 11 trades over 2026-08-17 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readHalozyme Therapeutics (HALO) appointed Dannielle Appelhans to its board. Appelhans has 20+ years of biotech and pharma experience, including CEO roles at COUR Pharmaceuticals and Rubius Therapeutics. She brings expertise in operations and manufacturing, aligning with Halozyme's growth strategy for ENHANZE, Hypercon, and Surf Bio technologies. Appelhans' leadership in scaling operations and executing partnerships is expected to benefit Halozyme's growth and shareholder value.
3 min read
